- NHC presents its draft Patient Stratification Tool for organizing patient input on benefit-risk (7/18/2013)
- NHC's letter to the Food and Drug Administration in response to the FDA’s call for comments on its draft benefit-risk plan (May 7, 2013)
- NHC’s proposed framework for patient engagement in drug development and approval processes (May 30, 2012)
- NHC's Executive Vice President and Chief Operating Officer Marc Boutin on BioCentury TV. (June 3, 2012)
Health care technologies, including drugs, devices, and diagnostics, have improved the diagnosis and treatment of many diseases. Today, advances in science continue to hold promise for the development of new treatment strategies in the future. Billions of dollars are spent annually on research, and development, and clinical trials to develop new health care products, yet patients may not be reaping the full return on investment. The creation of new treatments in both the public and private sector is vital to addressing these unmet medical needs.
To learn more about this initiative click here.
In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA). PDUFA is an agreement between the pharmaceutical industry and the FDA. Industry agrees to pay fees to the FDA in return for FDA meeting certain benchmarks, most notably faster review times. PDUFA has been reauthorized four times since the original agreement was passed by Congress. It was most recently reauthorized in July 2012, as part of the FDA Safety and Innovation Act.
During the negotiations for PDUFA, the NHC supported the provisions related to benefits and risks in the FDA decision-making process, biomarkers and patient reported outcomes in clinical trial design, and expanded resources for rare disease product development. All three provisions were included in the agreement between industry and FDA. The NHC also advocated for the inclusion of provisions in the Medical Device User Fee Act related to benefit-risk, the qualification of biomarkers, and the development of companion diagnostics.
On July 9, 2012, President Barack Obama signed into law the Food and Drug Administration Safety and Innovation Act. The NHC applauded Congress for their quick, bipartisan passage of the user fee legislation.
Click here to read a joint advertisement by patient and provider groups supporting PDUFA reauthorization.
The NHC has submitted the following comments to policymakers:
- NHC letter on the Sunshine Act and the impact it could have on research conducted and funded by p atient advocacy organizations (December 18, 2013)
To learn more about the NHC’s priority policy areas, please select one of the following issue areas: